A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19)
Status:
Completed
Trial end date:
2021-06-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from
getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an
injection into a vein. These participants will be matched to similar COVID-19 patients who
received other treatment at a local medical center. All participants will be followed to
learn how their disease responds. Participation could last about 3 months and includes two
required visits to the study site, with the remainder of assessments performed by phone or by
medical record review.